16. February 2023 | Corporate News

Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose

  • Major strategic developments in 2022 to boost future growth
  • Preliminary revenues stable at € 11.3 m for 2022 (2021: € 11.6 m) despite lack of milestone payments in 2022
  • Adjusted for the milestone payment in 2021, underlying revenues have increased by 16.5 %
  • Stable cash position with € 8.2 m and low cash drain

 

The full press release is available as download here: 

Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose
(59 KB)